Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Integrated 10-year analysis confirms safety profile abatacept

Integrated 10-year analysis confirms safety profile abatacept

Presented By
Dr Teresa Simon, Bristol-Myers Squibb, USA
EULAR 2019
Cohort study, ARTIS, RABBIT, FORWARD, British Columbia Canadian RA Cohort
The development of malignancy may be linked to the use of immunomodulators. Data suggests that the risks of overall, breast, or lung malignancies are not significantly increased in patients treated with abatacept [1]. These findings are consistent with the established safety profile of abatacept. Patients with rheumatoid arthritis (RA) are at an increased risk of malignancies compared with the general population [2]. Abatacept is a biologic immune modulator for RA, selectively blocking the specific interaction of CD80/CD86 receptors to CD28 and, therefore, inhibiting T cell proliferation and B cell immunological response. Abatacept has demonstrated efficacy and safety in the treatment of RA. “We have observed that, in clinical trial data, malignancy rates are similar for abatacept compared with placebo-treated patients and that post-marketing observational studies are valuable to assess the long-term risk associated with the medication,” said Dr Teresa Sim...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on